Listed by the USPTO as SPANGLER, JOSEPH RANKIN
Tech Center 1600 • Art Units: 1656
This examiner grants 42% of resolved cases
SPANGLER, JOSEPH RANKIN has 72 resolved cases in Tech Center 1600 and Art Unit 1656. The allowance rate is 41.7%, while the interview lift is 71.3%. The median time to allowance is 1346 days.
The listed companies are Toray Industries Inc., Chr. Hansen A/S, and Inbiose N V. The listed firms are BIRCH STEWART KOLASCH & BIRCH, LLP, Meunier Carlin & Curfman LLC, and TRASKBRITT, P.C. The interview measure is prominent relative to the allowance result, making interview preparation a practical consideration, although the resolved-case history remains limited.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18197579 | BIOANALYSIS OF THERAPEUTIC ANTIBODIES AND RELATED PRODUCTS USING IMMUNOPRECIPITATION AND NATIVE SEC-PCD-MS DETECTION | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18863697 | GENETICALLY MODIFIED YEAST AND FERMENTATION PROCESSES FOR THE PRODUCTION OF XYLITOL | Non-Final OA | Cargill, Incorporated |
| 17609841 | GENETICALLY MODIFIED MICROORGANISM FOR PRODUCING 3-HYDROXYHEXANEDIOIC ACID, (E)-HEX-2-ENEDIOIC ACID AND/OR HEXANEDIOIC ACID, AND PRODUCTION METHOD FOR SAID CHEMICALS | Non-Final OA | TORAY INDUSTRIES, INC. |
| 17609964 | GENETICALLY MODIFIED MICROORGANISM FOR PRODUCING 3-HYDROXYHEXANEDIOIC ACID, (E)-HEX-2-ENEDIOIC ACID AND/OR HEXANEDIOIC ACID, AND PRODUCTION METHOD FOR SAID CHEMICALS | Non-Final OA | TORAY INDUSTRIES, INC. |
| 17514264 | Fibrosis Assay | Final Rejection | Georgia Tech Research Corporation |
| 17415344 | ASPARAGINASE-INDUCED GLUTAMINE DEPLETION COMBINED WITH BCL-2 INHIBITION FOR TREATMENT OF HEMATOLOGIC AND SOLID CANCERS | Final Rejection | UNIVERSITY OF MARYLAND, BALTIMORE |
| 18558943 | SEQUENCE-DEFINED POLYMERS WITH ONE OR MORE AZIDES, METHODS OF MAKING, AND METHODS OF USE THEREOF | Non-Final OA | Yale University |
| 17602367 | METHOD AND APPARATUS FOR PURIFYING BLOOD | Final Rejection | B. Braun Avitum AG |
| 17613904 | METHODS OF MONITORING CELL CULTURE MEDIA | Non-Final OA | Bristol-Myers Squibb Company |
| 19048825 | FLAVONOID GLYCOSIDE GLYCOSYLTRANSFERASE LbUGT71BX1 IN LAPORTEA BULBIFERA AS WELL AS THE CODING GENE AND THE USE THEREOF | Non-Final OA | INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES |
| 17634909 | TEXTURING L. LACTIS WITH UNIQUE EPS GENE CLUSTERS | Non-Final OA | Chr. Hansen A/S |
| 16769964 | SPRAY-DRIED SIALYLLACTOSE | Final Rejection | Chr. Hansen A/S |
| 18835750 | CELLULOSE-SYNTHETIZING MICROBE TRANSFECTANT AND USE THEREOF | Non-Final OA | NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy41.7% of resolved applications examined by Joseph Rankin Spangler were allowed (72 resolved cases), compared with 44.3% across Art Unit 1656 over the last five years.
This examiner's interview lift is +71.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Joseph Rankin Spangler took 1,346 days on average from filing to allowance.
Joseph Rankin Spangler examines applications in Art Unit 1656 in Tech Center 1600 (Biotechnology & Pharmaceuticals).